EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access

Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification

Siqing Fu iD, Shuyang Yao, Yuan Yuan iD, Rebecca A Previs iD, Anthony D Elias iD, Richard D Carvajal iD, Thomas J George iD, Ying Yuan iD, Lihou Yu, Shannon N Westin iD, Yan Xing, Ecaterina E Dumbrava iD und 8 weitere

Journal of Clinical Oncology · 20.03.2023 · 41 (9) · 1725-1734

DOI: 10.1200/jco.22.00830 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.03.2023. Verfasst von Siqing Fu und 19 weiteren Autor:innen. Beteiligte Einrichtung: The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Antineoplastic Agents, Ovarian Neoplasms. Die Arbeit wurde bisher 110-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Preclinical cancer models harboring CCNE1 amplification were more sensitive to adavosertib treatment, a WEE1 kinase inhibitor, than models without amplification. Thus, we conducted this phase II study to assess the antitumor activity of adavosertib in patients with CCNE1-amplified, advanced refractory solid tumors. PATIENTS AND METHODS Patients aged ≥ 18 years with measurable disease and refractory solid tumors harboring CCNE1 amplification, an Eastern Cooperative Oncology Group performance status of 0-1, and adequate organ function were studied. Patients received 300 mg of adavosertib once daily on days 1 through 5 and 8 through 12 of a 21-day cycle. The trial followed Bayesian optimal phase II design. The primary end point was objective response rate (ORR). RESULTS Thirty patients were enrolled. The median follow-up duration was 9.9 months. Eight patients had partial responses (PRs), and three had stable disease (SD) ≥ 6 months, with an ORR of 27% (95% CI, 12 to 46), a SD ≥ 6 months/PR rate of 37% (95% CI, 20 to 56), a median progression-free survival duration of 4.1 months (95% CI, 1.8 to 6.4), and a median overall survival duration of 9.9 months (95% CI, 4.8 to 15). Fourteen patients with epithelial ovarian cancer showed an ORR of 36% (95% CI, 13 to 65) and SD ≥ 6 months/PR of 57% (95% CI, 29 to 82), a median progression-free survival duration of 6.3 months (95% CI, 2.4 to 10.2), and a median overall survival duration of 14.9 months (95% CI, 8.9 to 20.9). Common treatment-related toxicities were GI, hematologic toxicities, and fatigue. CONCLUSION Adavosertib monotherapy demonstrates a manageable toxicity profile and promising clinical activity in refractory solid tumors harboring CCNE1 amplification, especially in epithelial ovarian cancer. Further study of adavosertib, alone or in combination with other therapeutic agents, in CCNE1-amplified epithelial ovarian cancer is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsOvarian NeoplasmsFemaleHumansCarcinoma, Ovarian EpithelialBayes TheoremOncogene ProteinsCyclin EProtein-Tyrosine KinasesCell Cycle ProteinsPyrazolesPyrimidinones

Substanzen

Antineoplastic AgentsOncogene ProteinsCyclin EProtein-Tyrosine KinasesCell Cycle ProteinsadavosertibPyrazolesPyrimidinonesCCNE1 protein, humanWEE1 protein, human

Autor:innen und Institutionen

  • The University of Texas MD Anderson Cancer Center, Houston, TX.
  • City of Hope Comprehensive Cancer Center, Duarte, CA.
  • Duke University Medical Center, Durham, NC.
  • University of Colorado Cancer Center, Aurora, CO.
  • Columbia University Medical Center, New York, NY.
  • University of Florida Health Cancer Center, Gainesville, FL.

ORCID-Profile: Siqing Fu, Yuan Yuan, Rebecca A Previs, Anthony D Elias, Richard D Carvajal, Thomas J George, Ying Yuan, Shannon N Westin, Ecaterina E Dumbrava, Daniel D Karp, Apostolia M Tsimberidou, Jordi Rodon Ahnert, Naoko Takebe, Karen Lu, Funda Meric-Bernstam

Förderung

  • NCI NIH HHS

Zitieren

APA

Fu, S., Yao, S., Yuan, Y., Previs, R. A., Elias, A. D., Carvajal, R. D., George, T. J., Yuan, Y., Yu, L., Westin, S. N., Xing, Y., Dumbrava, E. E., Karp, D. D., Piha-Paul, S. A., Tsimberidou, A. M., Ahnert, J. R., Takebe, N., Lu, K., Keyomarsi, K., & Meric-Bernstam, F. (2023). Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. Journal of Clinical Oncology, 41(9), 1725-1734. https://doi.org/10.1200/jco.22.00830

Vancouver

Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, et al. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. Journal of Clinical Oncology. 2023;41(9):1725-1734. doi:10.1200/jco.22.00830

BibTeX
@article{Fu2023,
  author = {Fu, Siqing and Yao, Shuyang and Yuan, Yuan and Previs, Rebecca A and Elias, Anthony D and Carvajal, Richard D and George, Thomas J and Yuan, Ying and Yu, Lihou and Westin, Shannon N and Xing, Yan and Dumbrava, Ecaterina E and Karp, Daniel D and Piha-Paul, Sarina A and Tsimberidou, Apostolia M and Ahnert, Jordi Rodon and Takebe, Naoko and Lu, Karen and Keyomarsi, Khandan and Meric-Bernstam, Funda},
  title = {Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {9},
  pages = {1725--1734},
  doi = {10.1200/jco.22.00830}
}
Kostenlos starten →